Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Pay-Per-Treatment model brings Modulight order intake

By Antti SiltanenAnalyst
Modulight

Translation: Original published in Finnish on 11/8/2024 at 1:34 pm EET.

Modulight announced on Friday that it has secured contracts with a minimum cumulative value of EUR 1.5 MEUR over the next two years. The revenue stream consists of both clinical trials and commercial pilots. The news adds further visibility to the progress of the revenue and PPT model in the coming years. Our forecasts anticipate strong growth (2026 revenue 10.6 MEUR), to which the new contracts now announced will contribute. The announcement is in line with our growth projections, so we see no need to change our forecasts or view at this stage.

Contracts increase returns on PPT model

Modulight has invested in its Pay-Per-Treatment (PPT) model, where revenue is billed on the basis of the number of treatments performed. In its Q2'24 report, the company stated that the revenue generated by the PPT model exceeded 100 TEUR in the quarter. The contracts now announced are estimated to generate at least 1.5 MEUR over the next two years, or approximately 200 TEUR per quarter. The model's proceeds are thus growing in line with the company's objectives. According to the press release, customers have committed to minimum treatment volumes. Typically, PPT contracts are not subject to upfront commitments. Commitments are understandable, particularly in the case of clinical trials where the number of patients to be enrolled is known based on the study design. These contracts cover approximately 20 sites and involve customers including pharmaceutical and managed care companies, as well as hospitals and clinics in oncology and ophthalmology. We estimate that clinical trials and commercial pilots are project-based for Modulight. Progressing trials or pilots to the commercial stage would also provide the company with long-term ongoing revenue.

Contracts add visibility for the coming years

We expect Modulight’s 2024 revenue to be 3.9 MEUR. For the following year 2025, we forecast a change in revenue in euro terms of +2.8 MEUR, and in 2026 a further +2.7 MEUR. The contracts now announced are expected to generate annual revenue of just under 1 MEUR. The agreements therefore support the achievement of our estimates but are not sufficient on their own to make them a reality. Our forecasts thus include an expectation of further rapid positive developments beyond these new contracts. The news is fully in line with our expectations and supports their achievement. The contracts will contribute to the very welcome visibility of Modulight's revenue development.

Login required

This content is only available for logged in users

Create account

Modulight operates in the technology industry. The company designs, markets, and produces biomedical laser products used in oncology, genetics, and ophthalmology. The customers primarily consist of hospitals and corporate customers operating in medical technology. In addition to the main business, various value-added services are also offered. Their main market is the US.

Read more on company page

Key Estimate Figures22.10.2024

202324e25e
Revenue4.03.97.7
growth-%-12.5 %-4.1 %99.6 %
EBIT (adj.)-12.1-8.1-6.3
EBIT-% (adj.)-301.4 %-210.9 %-81.7 %
EPS (adj.)-0.28-0.18-0.12
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

Has there been any significant or noteworthy development in the IQM and Modulight quantum computing collaboration, or is it just a basic partnership...
12/3/2025, 6:05 PM
by Salkunvartija97
1
Good company presentation. Exuding confidence. Also remembered the 2024 talks about commercialization. Now said that there hasn’t been anything...
11/27/2025, 8:20 PM
by Jopinaattori
1
A new, just under half an hour long Modu and Orsila.https://youtu.be/tk0nQENR9DU?si=9MU7U32q6KifMSdf&t=4
11/27/2025, 7:14 PM
by Maakinen
3
My previous message in the thread 4 years ago. Modu designs lasers, which is potentially a very lucrative part of the value chain, if it can...
11/27/2025, 6:20 PM
by Clark kent
5
I also recently invested a bit in Modulight. I’ve also noticed the quietness; it’s clearly the quietest company among my investments.
11/27/2025, 3:19 PM
by Salkunvartija97
1
It’s quiet, regrettably quiet. Trading is almost at zero. This is how the years pass, big promises have turned into silence.
11/27/2025, 3:11 PM
by Skipper
1
Orsila has bought 21,000 units. A good sign for me.
10/29/2025, 9:08 AM
by Jopinaattori
8
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.